The newly available service, known as SpinOculation C-Pro Protocol Software, was designed to run on the company’s Sepax C-Pro Cell Processing System, and is expected to facilitate and accelerate the cell transduction step, during the manufacturing of chimeric antigen receptor (CAR)-T therapies.
Catarina Flyborg, GM of cell and gene therapy at GE Healthcare, commented that the launch of the service answers a need for advanced technologies to support cell and gene therapy manufacturing, since it can simplify a ‘critical’ step in the cell therapy workflow.
The software automates the transduction phase of the process, which so far has been done manually. Moreover, it enables users to choose the volume and cell concentration from the steps of cell preparation through to transduction and final resuspension.
According to GE Healthcare, automation of the process means enhanced security and sterility of the end product, reduced manipulations and time required, as well as maintaining cell viability and virus stability.
A spokesperson for the company told us that GE Healthcare is also looking to automate further parts of the process, aiming for improved efficiency and speed.
SpinOculation is the only stand-alone software solution on the market for this purpose, providing a closed, reproducible and traceable operative service.
Additionally, according to the company, the technology has the potential to optimize performance through adjustments of the open system parameters by the user.